Update on entecavir in the management of severe forms of Hepatitis B
Despite the effective management of most cases of hepatitis B virus (HBV) infection, there is still much room for improvement in the treatment of more severe cases of hepatitis B, such as those occurring in patients with decompensated cirrhosis, in transplanted subjects, and in patients with exacerb...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2012
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3953733/ |
| id |
pubmed-3953733 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-39537332014-04-02 Update on entecavir in the management of severe forms of Hepatitis B Sacco, Rodolfo Review Despite the effective management of most cases of hepatitis B virus (HBV) infection, there is still much room for improvement in the treatment of more severe cases of hepatitis B, such as those occurring in patients with decompensated cirrhosis, in transplanted subjects, and in patients with exacerbations of HBV infection. Among the treatments currently approved for the therapy of hepatitis B, entecavir determines a rapid suppression of viral load. This drug is also associated with a high genetic barrier and an overall favorable safety profile. This review provides an overview of recent evidence related to the use of entecavir in the management of the most severe forms of hepatitis B. The results obtained for this drug in real-life clinical practice are also reviewed. Dove Medical Press 2012-05-15 /pmc/articles/PMC3953733/ /pubmed/24696620 http://dx.doi.org/10.2147/HMER.S16136 Text en © 2012 Sacco, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Sacco, Rodolfo |
| spellingShingle |
Sacco, Rodolfo Update on entecavir in the management of severe forms of Hepatitis B |
| author_facet |
Sacco, Rodolfo |
| author_sort |
Sacco, Rodolfo |
| title |
Update on entecavir in the management of severe forms of Hepatitis B |
| title_short |
Update on entecavir in the management of severe forms of Hepatitis B |
| title_full |
Update on entecavir in the management of severe forms of Hepatitis B |
| title_fullStr |
Update on entecavir in the management of severe forms of Hepatitis B |
| title_full_unstemmed |
Update on entecavir in the management of severe forms of Hepatitis B |
| title_sort |
update on entecavir in the management of severe forms of hepatitis b |
| description |
Despite the effective management of most cases of hepatitis B virus (HBV) infection, there is still much room for improvement in the treatment of more severe cases of hepatitis B, such as those occurring in patients with decompensated cirrhosis, in transplanted subjects, and in patients with exacerbations of HBV infection. Among the treatments currently approved for the therapy of hepatitis B, entecavir determines a rapid suppression of viral load. This drug is also associated with a high genetic barrier and an overall favorable safety profile. This review provides an overview of recent evidence related to the use of entecavir in the management of the most severe forms of hepatitis B. The results obtained for this drug in real-life clinical practice are also reviewed. |
| publisher |
Dove Medical Press |
| publishDate |
2012 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3953733/ |
| _version_ |
1612067691528454144 |